Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

← catalyst calendar

NCT05758077 · readout ≤ 133 d

Sponsored by SeaStar Medical (industry) · ICU — their whole pipeline →.

Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
339estimated
Sites
38
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-04-17actualWhen the study began enrolling
Primary completionDec 2026estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionJun 2027estimatedThe whole study's end, after follow-up
First posted2023-03-07actualWhen this record first appeared on the registry
Results posted—When the sponsor posted results to the registry
Record updated2026-04-23actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Acute Kidney Injury

Interventions

  • Device: Selective Cytopheretic Device — also filed as SCD
  • Other: Standard of Care

Primary outcome

what the primary-completion date above is the date OF
Composite endpoint of mortality or dialysis dependency at 90 days
measured 90 days

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ICU's whole pipeline · Catalyst calendar · Every registered study · What changed

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)